Phaseline

Companies › Boulder Care

Boulder Care: clinical trials, targets and expected readouts

1 active drug program in 35 registered trials: 20 Phase 4, 7 Phase 2, 5 Phase 3, 3 Phase 1; Neurology, Oncology, Other, Psychiatry; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Buprenorphine
Mu opioid receptor agonist; Kappa opioid receptor agonist
OPRM1, OPRK1Phase 1Opioid Use Disorder; Postoperative Pain; Pain, Postoperative; Acute Postoperative Pain …Aug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06742554BuprenorphinePhase 4Postoperative PainOtherApr 2025
NCT04408313BuprenorphinePhase 2Opioid-use DisorderPsychiatryMay 2026
NCT05824832BuprenorphinePhase 4Pain, PostoperativeOtherJun 2026
NCT07524738BuprenorphinePhase 3Opioid Use DisorderPsychiatryJul 2026
NCT07439549BuprenorphinePhase 4Opioid Use DisorderPsychiatrySep 2026
NCT07439549BuprenorphinePhase 4Opioid Use DisorderPsychiatrySep 2026
NCT06051890BuprenorphinePhase 4Opioid Use DisorderPsychiatryDec 2026
NCT05778591BuprenorphinePhase 2SchizophreniaPsychiatryDec 2026
NCT07430345BuprenorphinePhase 1FractureOtherDec 2026
NCT05589181BuprenorphinePhase 3Opioid Use DisorderPsychiatryDec 2026
NCT06379984BuprenorphinePhase 2Opioid Use DisorderPsychiatryDec 2026
NCT04464980BuprenorphinePhase 2Opioid Use Disorder (OUD)PsychiatryDec 2026
NCT04464980BuprenorphinePhase 2Opioid Use Disorder (OUD)PsychiatryDec 2026
NCT06880718BuprenorphinePhase 4Opioid Use DisorderPsychiatryJan 2027
NCT06880718BuprenorphinePhase 4Opioid Use DisorderPsychiatryJan 2027
NCT03646058BuprenorphinePhase 3Suicidal IdeationPsychiatryJan 2027
NCT06441604BuprenorphinePhase 2Opioid Use DisorderPsychiatryJan 2027
NCT07176351BuprenorphinePhase 4Opioid Use DisorderPsychiatryFeb 2027
NCT06949826BuprenorphinePhase 4Pain, PostoperativePsychiatryMar 2027
NCT07434427BuprenorphinePhase 4Acute Postoperative PainNeurologyMay 2027
NCT06316830BuprenorphinePhase 2Opioid Use DisorderPsychiatryAug 2027
NCT07169409BuprenorphinePhase 1Opioid Use DisorderPsychiatryAug 2027
NCT06494904BuprenorphinePhase 3Opioid Use DisorderPsychiatrySep 2027
NCT05988710BuprenorphinePhase 4AnalgesiaPsychiatryJan 2028
NCT05988710BuprenorphinePhase 4AnalgesiaPsychiatryJan 2028
NCT05988710BuprenorphinePhase 4AnalgesiaPsychiatryJan 2028
NCT06442566BuprenorphinePhase 1Opioid WithdrawalPsychiatryMar 2028
NCT07786012BuprenorphinePhase 4Cesarean DeliveryOtherAug 2028
NCT04375033BuprenorphinePhase 4Opioid Use DisorderPsychiatrySep 2028
NCT04375033BuprenorphinePhase 4Opioid Use DisorderPsychiatrySep 2028
NCT06323824BuprenorphinePhase 4Opioid Use DisorderPsychiatryDec 2028
NCT06306443BuprenorphinePhase 3Opioid Use DisorderPsychiatryJan 2029
NCT06574009BuprenorphinePhase 4Chronic PainOncologyApr 2029
NCT04811014BuprenorphinePhase 4Opioid-use DisorderPsychiatryAug 2030
NCT07485335BuprenorphinePhase 4Opioid Use DisorderPsychiatrySep 2030

Targets

OPRM1 (1) OPRK1 (1)

Companies with the same targets

Trevi Therapeutics Currax Pharmaceuticals AgelessRx ReacX Pharmaceuticals Akyso Therapeutics Inventage Lab. Adneuris Therapeutics Alkermes Shionogi Ensysce Biosciences

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.